Growth Investors: Industry Analysts Just Upgraded Their Core Lithium Ltd (ASX:CXO) Revenue Forecasts By 13%
Core Lithium Ltd (ASX:CXO) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts have sharply increased their revenue numbers, with a view that Core Lithium will make substantially more sales than they'd previously expected.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
Following the upgrade, the consensus from four analysts covering Core Lithium is for revenues of AU$675k in 2025, implying a disturbing 99% decline in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of AU$595k in 2025. It looks like there's been a clear increase in optimism around Core Lithium, given the solid increase in revenue forecasts.
See our latest analysis for Core Lithium
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Core Lithium's past performance and to peers in the same industry. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 99% by the end of 2025. This indicates a significant reduction from annual growth of 75% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 6.5% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Core Lithium is expected to lag the wider industry.
The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. They also expect company revenue to perform worse than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Core Lithium.
Analysts are definitely bullish on Core Lithium, but no company is perfect. Indeed, you should know that there are several potential concerns to be aware of, including a short cash runway. For more information, you can click through to our platform to learn more about this and the 2 other risks we've identified .
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Nvidia insiders sold over $1 billion in stock amid market surge, FT reports
(Reuters) -Nvidia insiders sold over $1 billion worth of company stock in the past year, with a notable uptick in recent trading activity as executives capitalize on surging investor interest in artificial intelligence, the Financial Times reported on Sunday. More than $500 million of the share sales took place this month as the California-based chips designer's share price climbed to an all-time high, the report said. Jensen Huang, Nvidia's chief executive, started selling shares this week for the first time since September, the SEC filing showed. Nvidia's stock hit a record on Wednesday, and the chipmaker reclaimed the crown as the world's most valuable company after an analyst said the chipmaker was set to ride a "Golden Wave" of artificial intelligence. Its latest gains reflect the U.S. stock market's return to the "AI trade" that fueled massive gains in chip stocks and related technology companies in recent years on optimism about the emerging technology. Nvidia did not immediately respond to a Reuters request for comment. Nvidia's shares have rebounded over 60% from their closing low on April 4, when Wall Street was reeling from President Donald Trump's global tariff announcements. U.S. stocks, including Nvidia, have recovered on expectations the White House will reach trade deals to soften the tariffs. Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
2 hours ago
- Yahoo
Big price increase for one city
Public transport users in Sydney will soon fork out more for their trips as Opal fares are set to increase. From July 14 most fares will be adjusted in line with the annual consumer price index movement. This means an average increase of 2.5 per cent across Opal fares and single trip tickets. Adult customers will have a new daily travel cap of $19.30 between Monday and Thursday, and $9.65 between Friday and Sunday, and on public holidays. That is an increase of 60c on weekday travel and 30c on weekends. The cap for children and concession card holders will jump to a daily weekday cap of $9.65, while the weekend and public holiday cap will hop up to $4.80. That increase is 30c on weekdays and 15c on weekends. Airport travellers will also face an increase, with the station access fee increasing from $17.34 to $17.92 for adults — a 58c increase — and from $15.50 to $16.03 for kids, seniors and concession card holders — a 53c increase. The weekly airport travel cap of $35.16 for adults and $31.51 for kids and concession card holders will increase to$36.36 and $32.58 respectively. Weekly travel caps on the network will remained capped at $50 for adults and $25 for children and concession card holders, while seniors and pensioners with a Gold Opal card will still be charged no more than $2.50 a day. Transport for NSW Secretary Josh Murray said the fare increases were necessary to help recover the cost of running the network. 'We've leveraged the discounts available to us to protect the hip pockets of those most reliant on our public transport system,' Mr Murray said. 'We've done our best to minimise the impact on passengers and the 14 July changes will see average weekly adult travel costs go up by an average of $0.50, and less than $1 for 99 per cent of passengers' Mr Murray said.
Yahoo
2 hours ago
- Yahoo
Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.
I have owned Johnson & Johnson in the past. I like the company's business and its strong history of rewarding investors. There's one problem I just can't get past today. 10 stocks we like better than Johnson & Johnson › Johnson & Johnson (NYSE: JNJ) is an iconic U.S. healthcare giant. It has changed over the years, but today its focus is on pharmaceuticals and medical devices. And it is an industry leader in both spaces. There are a lot of positives with J&J, as it is more commonly known on Wall Street, but there's one dark cloud that I can't ignore. And the shadow from that cloud is why I just can't justify buying Johnson & Johnson today. When I look for stocks, I generally start with the dividend. And I don't look at the yield, instead focusing on the dividend growth streak. The longer a company has increased its dividend, the better, since only financially strong and well-run companies can hike the dividend year in and year out. J&J's streak is a huge 63 years, making it a Dividend King. I own a lot of Dividend Kings because I believe it is a clear indication that a business is well run. I also look at dividend yield. On that front, J&J's dividend yield is roughly 3.4% today. That's well above the S&P 500 index's 1.2% average yield and the average 1.7% in the healthcare sector. But, more to the point, it happens to be toward the high end of the historical yield range for Johnson & Johnson. That suggests this reliable dividend stock is not only offering an attractive yield, but it also looks attractively priced. On the valuation front, more traditional valuation metrics clearly back up the value proposition. J&J's price-to-sales, price-to-earnings, and price-to-book value ratios are all below their five-year averages. I haven't discussed the actual business, and Johnson & Johnson already looks like a strong buy. The business, meanwhile, just so happens to be one of the largest in the pharmaceutical and medical device spaces. J&J has the size and scale to invest heavily in research and development, regularly bringing out attractive new products. It has manufacturing, marketing, and distribution prowess that few can match. And it is generally a very well-respected supplier, so buyers are happy to work with Johnson & Johnson. And still I won't buy it and think that most others should avoid it, too. The problem with Johnson & Johnson is that I just can't overlook its talcum powder products. Or, more precisely, the class action lawsuits involving its talcum powder products. Past users claimed that J&J's talcum powder causes cancer. J&J denies this and is fighting the civil claims in court. The lawsuit numbers and liabilities are huge, well into the thousands of claimants and billions of dollars. To put some figures on it, there are over 60,000 lawsuits against J&J, and it recently tried to settle the issue with a $10 billion class action settlement offer. The details of the offer didn't pass muster with the judge overseeing the case, and it was denied. My real issue, however, isn't just the potential cost. It is how uncertain the outcome is in what amounts to a super high-profile problem. If the class action case goes to a jury trial, there's no telling what happens, and the case could linger for years as both sides continue to fight, as they almost certainly will. And, worse, J&J can't discuss the problem with shareholders because it is a sensitive legal issue. I don't blame management for not talking about the details of the lawsuits. The legal decisions J&J makes have to be kept private. But, at the same time, investors are mostly left in the dark as to what the company is going to do and why. I don't mind owning companies facing hardship, and I think J&J will survive the legal headwinds it faces. But from experience, I know I don't want to own companies that aren't able to discuss in reasonable detail what they are doing about the hardships they face. So, I can't, in good conscience, suggest anyone buy Johnson & Johnson because I wouldn't buy the stock myself right now. Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,731!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $945,846!* Now, it's worth noting Stock Advisor's total average return is 818% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It. was originally published by The Motley Fool
